A recent meta-analysis examined and validated biomarkers of response to immune-checkpoint inhibitors (ICIs). Herein, we discuss the findings of this analysis, which are consistent with previously identified determinants of ICI efficacy and demonstrate that some genetic variables influence response across multiple cancer types.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).
Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
Lee, J. S. & Ruppin, E. Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1. JAMA Oncol. 5, 1614–1618 (2019).
Anagnostou, V. et al. Integrative tumor and immune cell multi-omic analyses predict response to immune checkpoint blockade in melanoma. Cell Rep. Med. 1, 100139 (2020).
Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596–614 (2021).
Chowell, D. et al. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat. Med. 25, 1715–1720 (2019).
McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463–1469 (2016).
Morris, L. G. T. et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget 7, 10051–10063 (2016).
Qu, Y. et al. Baseline frequency of inflammatory Cxcl9-expressing tumor-associated macrophages predicts response to avelumab treatment. Cell Rep. 32, 107873 (2020).
Cheng, S. et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 184, 792–809 (2021).
Acknowledgements
The authors acknowledge funding sources including NIH R01 CA205426 and NIH R35 CA232097 (to T.A.C.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
T.A.C. is a co-founder and holds equity in Gritstone Oncology; holds equity in An2H; acknowledges grant funding from and has been an advisor for An2H, AstraZeneca, Bristol–Myers Squibb, Eisai, Illumina and Pfizer; has been an advisor for MedImmune; and holds ownership of intellectual property on using tumour mutation burden to predict immunotherapy response, with a patent pending, which has been licensed to PGDx. T.J.A. declares no competing interests.
Rights and permissions
About this article
Cite this article
Alban, T.J., Chan, T.A. Immunotherapy biomarkers: the long and winding road. Nat Rev Clin Oncol 18, 323–324 (2021). https://doi.org/10.1038/s41571-021-00498-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00498-w
